The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Alfimova M.V.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN

Korovaĭtseva G.I.

Nauchnyĭ tsentr psikhicheskogo zdorovia RAMN, Moskva

Lezheiko T.V.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN, Moskva

Golubev S.A.

Snegireva A.A.

GKUZ "Moskovskaia gorodskaia klinicheskaia psikhiatricheskaia bol'nitsa #1 im. N.A. Alekseeva", Moskva

Sakharova E.A.

Volgogradskiĭ oblastnoĭ klinicheskiĭ onkologicheskiĭ dispanser #1

Golimbet V.E.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN, Moskva

The interaction effect of ANKK1/DRD2 TaqIA and HTR2C Cys23Ser on approach motivation in schizophrenic patients and normals

Authors:

Alfimova M.V., Korovaĭtseva G.I., Lezheiko T.V., Golubev S.A., Snegireva A.A., Sakharova E.A., Golimbet V.E.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(7): 67‑72

DOI: 10.17116/jnevro20181187167

Read: 1053 times

Contact the author
Table of contents

THE INTERACTION EFFECT OF ANKK1/DRD2 TAQIA AND HTR2C CYS23SER ON APPROACH MOTIVATION IN SCHIZOPHRENIC PATIENTS AND NORMALS
THE INTERACTION EFFECT OF ANKK1/DRD2 TAQIA AND HTR2C CYS23SER ON APPROACH MOTIVATION IN SCHIZOPHRENIC PATIENTS AND NORMALS

To cite this article:

Alfimova MV, Korovaĭtseva GI, Lezheiko TV, Golubev SA, Snegireva AA, Sakharova EA, Golimbet VE. The interaction effect of ANKK1/DRD2 TaqIA and HTR2C Cys23Ser on approach motivation in schizophrenic patients and normals. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(7):67‑72. (In Russ.)
https://doi.org/10.17116/jnevro20181187167

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Search for info­rmative predictors of the deve­lopment and progression of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):124-130
The role of the rs1800795 poly­morphism of the inte­rleukin 6 gene in the deve­lopment of cognitive defi­cits asso­ciated with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):113-120
Migraine: issues of pathogenesis and drug therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;(1):45-52
Gastrointestinal failure in postoperative period. Russian Journal of Anesthesiology and Reanimatology. 2025;(6):107-117
Comparative evaluation of the effi­cacy of semi-elemental and poly­meric nutritional formulas in combination with sero­tonin for the correction of nutritional status diso­rders and gastrointestinal insu­fficiency in the postoperative period in onco­logical patients: resu­lts of a pilot study. Russian Journal of Anesthesiology and Reanimatology. 2026;(2):84-92
Poly­morphism of the COMT, OPRM1, CYP2D6, CYP2B6, CYP2C9 genes and effe­ctiveness of analgesia in cardiac surgery. Russian Journal of Anesthesiology and Reanimatology. 2026;(3):6-16
Asso­ciation of rs1042713 and rs1042714 poly­morphisms of the ADRB2 gene with response to beta-blockers in the mana­gement of portal hype­rtension in patients with liver cirrhosis. Russian Journal of Evidence-Based Gastroenterology. 2026;(2):5-12
Abstract:

Objective. To evaluate the association of the DRD2 gene and DRD2 x HTR2C interaction with hedonic and activational aspects of approach motivation in schizophrenia. Material and methods. Genotypes at polymorphic loci DRD2 rs1800497 and HTR2C rs6318 (Cys23Ser) were identified in a sample that included 174 patients with schizophrenic spectrum disorders and 268 healthy subjects without a family history of psychoses. The participants completed the BIS/BAS and Temporal Experience of Pleasure Scale (TEPS). Results and conclusion. A MANCOVA with sex and age as covariates revealed the effect of the «DRD2 x HTR2C x diagnosis» interaction on the BAS scores (p=0.033). The effect was significant for the Fun-Seeking and Drive scales. Among patients, the carriers of the DRD2 TT/CT x HTR2C GG/G genotype showed the highest scores on the both scales, and those with the minor alleles in the two loci had the lowest ones. Differences between these groups were nominally significant for both the Fun-Seeking and Drive, but did not survive the correction for multiple comparisons. Among controls, subjects without minor alleles demonstrated the highest scores on these two scales. They differed significantly from the carriers of the DRD2 TT/CT+HTR2C GG/G genotype on the Fun-Seeking (p=0.008). No effects of DRD2 and HTR2C on TEPS scores were found. In general, the results of the study can be interpreted in favor of the hypothesis about the role of the HTR2C and DRD2 genes interaction in the variability of the activational aspects of approach motivation in schizophrenia and healthy subjects. However, the lack of differences survived correction for multiple comparisons makes it difficult to interpret the revealed effects.

Keywords:

psychosis
motivation
pleasure
dopamine
serotonin
genetic polymorphism
gene X gene interaction

Authors:

Alfimova M.V.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN

Korovaĭtseva G.I.

Nauchnyĭ tsentr psikhicheskogo zdorovia RAMN, Moskva

Lezheiko T.V.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN, Moskva

Golubev S.A.

Snegireva A.A.

GKUZ "Moskovskaia gorodskaia klinicheskaia psikhiatricheskaia bol'nitsa #1 im. N.A. Alekseeva", Moskva

Sakharova E.A.

Volgogradskiĭ oblastnoĭ klinicheskiĭ onkologicheskiĭ dispanser #1

Golimbet V.E.

Nauchnyĭ tsentr psikhicheskogo zdorov'ia RAMN, Moskva

Close metadata

References:

  1. Fervaha G, Foussias G, Agid O, Remington G. Motivational deficits in early schizophrenia: prevalent, persistent, and key determinants of functional outcome. Schizophrenia Research. 2015;166(1-3):9-16. https://doi.org/10.1016/j.schres.2015.04.040
  2. Soares-Cunha C, Coimbra B, Sousa N, Rodrigues AJ. Reappraising striatal D1- and D2-neurons in reward and aversion. Neuroscience & Biobehavioral Reviews. 2016;68:370-386. https://doi.org/10.1016/j.neubiorev.2016.05.021
  3. Gluskin BS, Mickey BJ. Genetic variation and dopamine D2 receptor availability: a systematic review and meta-analysis of human in vivo molecular imaging studies. Translational Psychiatry. 2016;6:747. https://doi.org/10.1038/tp.2016.22
  4. Kibitov AO. Genetics of substance abuse: the molecular-genetic profile of dopamine neurotransmitter system for alcoholism and opiate addiction. Narkologia. 2011;10(9):25-42. (In Russ.)
  5. Bühler KM, Giné E, Echeverry-Alzate V, Calleja-Conde J, de Fonseca FR, López-Moreno JA. Common single nucleotide variants underlying drug addiction: more than a decade of research. Addiction Biology. 2015;20(5):845-871. https://doi.org/10.1111/adb.12204
  6. Cohen MX, Young J, Baek JM, Kessler C, Ranganath C. Individual differences in extraversion and dopamine genetics predict neural reward responses. Cognitive Brain Research. 2005;25(3):851-861. https://doi.org/10.1016/j.cogbrainres.2005.09.018
  7. Felsted JA, Ren X, Chouinard-Decorte F, Small DM. Genetically determined differences in brain response to a primary food reward. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2010;30(7):2428-2432. https://doi.org/10.1523/JNEUROSCI.5483-09.2010
  8. Nikolova YS, Ferrell RE, Manuck SB, Hariri AR. Multilocus Genetic Profile for Dopamine Signaling Predicts Ventral Striatum Reactivity. Neuropsychopharmacology. 2011;36(9):1940-1947. https://doi.org/10.1038/npp.2011.82
  9. Stice E, Yokum S, Burger K, Epstein H, Smolen A. Multilocus Genetic Composite Reflecting Dopamine Signaling Capacity Predicts Reward Circuitry Responsivity. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2012;32(29):10093-10100. https://doi.org/10.1523/JNEUROSCI.1506-12.2012
  10. Richter A, Barman A, Wüstenberg T, Soch J, Schanze D, Deibele A, Behnisch G, Assmann A, Klein M, Zenker M, Seidenbecher C, Schott BH. Behavioral and Neural Manifestations of Reward Memory in Carriers of Low-Expressing versus High-Expressing Genetic Variants of the Dopamine D2 Receptor. Frontiers in Psychology. 2017;8:654. https://doi.org/10.3389/fpsyg.2017.00654
  11. Reuter M, Schmitz A, Corr P, Hennig J. Molecular genetics support Gray’s personality theory: The interaction of COMT and DRD2 polymorphisms predicts the behavioural approach system. International Journal of Neuropsychopharmacology. 2006;9(2):155-166. https://doi.org/10.1017/S1461145705005419
  12. Lee SH, Ham BJ, Cho YH, Lee SM, Shim SH. Association study of dopamine receptor D2 TaqI A polymorphism and reward-related personality traits in healthy Korean young females. Neuropsychobiology. 2007;56(2-3):146-151. https://doi.org/10.1159/000115781
  13. Davis C, Levitan RD, Kaplan AS, Carter J, Reid C, Curtis C, Patte K, Hwang R, Kennedy JL. Reward sensitivity and the D2 dopamine receptor gene: A case-control study of binge eating disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2008;32(3):620-628. https://doi.org/10.1016/j.pnpbp.2007.09.024
  14. Montag C, Buckholtz JW, Hartmann P, Merz M, Burk C, Hennig J, Reuter M. COMT genetic variation affects fear processing: psychophysiological evidence. Behavioral Neuroscience. 2008;122(4):901-909. https://doi.org/10.1037/0735-7044.122.4.901
  15. Johnson SL, Carver CS, Joormann J, Cuccaro ML. Genetic polymorphisms related to behavioral approach and behavioral inhibition scales. Personality and Individual Differences. 2016;88:251-255. https://doi.org/10.1016/j.paid.2015.09.024
  16. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological Insights From 108 Schizophrenia-Associated Genetic Loci. Nature. 2014;511(7510):421-427. https://doi.org/10.1038/nature13595
  17. Brisch R, Saniotis A, Wolf R, Bielau H, Bernstein H, Steiner J, Bogerts B, Braun K, Jankowski Z, Kumaratilake J, Henneberg M, Gos T. The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue. Frontiers in Psychiatry. 2014;5:47. https://doi.org/10.3389/fpsyt.2014.00047
  18. Zahari Z, Teh LK, Ismail R, Razali SM. Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia. Psychiatric Genetics. 2011;21(4):183-189. https://doi.org/10.1097/YPG.0b013e3283437250
  19. Kang SG, Na KS, Lee HJ, Chee IS, Lee K, Lee J. DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks’ amisulpride treatment. Journal of Clinical Psychopharmacology. 2015;35(2):158-162. https://doi.org/10.1097/JCP.0000000000000294
  20. Eisenstein SA, Bogdan R, Chen L, Moerlein SM, Black KJ, Perlmutter JS, Hershey T, Barch DM. Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia. Journal of Psychiatric Research. 2017;86:9-17. https://doi.org/10.1016/j.jpsychires.2016.11.007
  21. Kring AM, Barch DM. The motivation and pleasure dimension of negative symptoms: Neural substrates and behavioral outputs. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. 2014;24(5):725-736. https://doi.org/10.1016/j.euroneuro.2013.06.007
  22. Salamone JD, Yohn SE, López-Cruz L, San Miguel N, Correa M. Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology. Brain. 2016;139:1325-1347. https://doi.org/10.1093/brain/aww050
  23. Der-Avakian A, Markou A. The Neurobiology of Anhedonia and Other Reward-Related Deficits. Trends in Neurosciences. 2012;35(1):68-77. https://doi.org/10.1016/j.tins.2011.11.005
  24. Pogorelov VM, Rodriguiz RM, Cheng J, Huang M, Schmerberg CM, Meltzer HY, Roth BL, Kozikowski AP, Wetsel WC. 5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice. Neuropsychopharmacology. 2017;42(11):2163-2177. https://doi.org/10.1038/npp.2017.52
  25. Howell LL, Cunningham KA. Serotonin 5-HT2 Receptor Interactions with Dopamine Function: Implications for Therapeutics in Cocaine Use Disorder. Pharmacological Reviews. 2015;67(1):176-197. https://doi.org/10.1124/pr.114.009514
  26. Simpson EH, Kellendonk C, Ward RD, Richards V, Lipatova O, Fairhurst S, Kandel ER, Balsam PD. Pharmacologic Rescue of Motivational Deficit in an Animal Model of the Negative Symptoms of Schizophrenia. Biological psychiatry. 2011;69(10):928-935. https://doi.org/10.1016/j.biopsych.2011.01.012
  27. Simpson EH, Waltz JA, Kellendonk C, Balsam PD. Schizophrenia in Translation: Dissecting Motivation in Schizophrenia and Rodents. Schizophrenia Bulletin. 2012;38(6):1111-1117. https://doi.org/10.1093/schbul/sbs114
  28. Sumiyoshi T, Kunugi H, Nakagome K. Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia. Frontiers in Neuroscience. 2014; 8:395. https://doi.org/10.3389/fnins.2014.00395
  29. Okada M, Northup JK, Ozaki N, Russell JT, Linnoila M, Goldman D. Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution. Molecular Psychiatry. 2004;9:55-64. https://doi.org/10.1038/sj.mp.4001357
  30. Fentress HM, Grinde E, Mazurkiewicz JE, Backstrom JR, Herrick-Davis K, Sanders-Bush E. Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms. The Pharmacogenomics Journal. 2005;5:244-254. https://doi.org/10.1038/sj.tpj.6500315
  31. Knyazev GG, Slobodskaya HR, Wilson GD. Comparison of construct validity of the Gray—Wilson personality questionnaire and the BIS/BAS scales. Personality and Individual Differences. 2004;37(8):1565-1582. https://doi.org/10.1016/j.paid.2004.02.013
  32. Monakhov M, Golimbet V, Abramova L, Kaleda V, Karpov V. Association study of three polymorphisms in the dopamine D2 receptor gene and schizophrenia in the Russian population. Schizophrenia Research. 2008;100:302-307. https://doi.org/10.1016/j.schres.2008.01.007
  33. Alfimova MV, Golimbet VE, Korovaitseva GI, Abramova LI, Kaleda VG. Association Between Serotonin Receptor 2c Gene Cys23Ser Polymorphism and Social Behavior in Schizophrenia Patients and Healthy Individuals. Russian Journal of Genetics. 2015;51(2):198-203. https://doi.org/10.1134/S1022795415010020.
  34. Beeler JA, Faust RP, Turkson S, Ye H, Zhuang X. Low Dopamine D2 Receptor Increases Vulnerability to Obesty Via Reduced Physical Activity Not Increased Appetitive Motivation. Biological psychiatry. 2016;79(11):887-897. https://doi.org/10.1016/j.biopsych.2015.07.009
  35. Trifilieff P, Martinez D. Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity. Neuropharmacology. 2014;76(00):498-509. https://doi.org/10.1016/j.neuropharm.2013.06.031
  36. Lerer B, Macciardi F, Segman RH, Adolfsson R, Blackwood D, Blairy S, Del Favero J, Dikeos DG, Kaneva R, Lilli R, Massat I, Milanova V, Muir W, Noethen M, Oruc L, Petrova T, Papadimitriou GN, Rietschel M, Serretti A, Souery D, Van Gestel S, Van Broeckhoven C, Mendlewicz J. Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Molecular Psychiatry. 2001;6(5):579-585. https://doi.org/10.1038/sj.mp.4000883
  37. Brummett BH, Babyak MA, Williams RB, Harris KM, Jiang R, Kraus WE, Singh A, Costa PT, Georgiades A, Siegler IC. A putatively functional polymorphism in the HTR2C gene is associated with depressive symptoms in white females reporting significant life stress. PLoS One. 2014;9(12):114451. https://doi.org/10.1371/journal.pone.0114451
  38. Vyalova NM, Pozhidaev IV, Osmanova DZ, Simutkin GG, Ivanova SA, Bokhan NA. Association of polymorphic variants of PIP5K2A and HTR2C genes with response to antidepressant therapy of patients with a current depressive episode. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(5):58-61. (In Russ.) https://doi.org/10.17116/jnevro20171175158-61
  39. Alfimova MV, Lezheiko TV, Korovaitseva GI, Golimbet VE. Psychological and Molecular-Genetic Mechanism of Machiavellianism Reduction in Schizophrenia. Psihologiya. Zhurnal vysshej shkoly ehkonomiki. 2015;12(2)70-92. (In Russ.)
  40. Katz AC, Sarapas C, Bishop JR, Patel SR, Shankman SA. The Mediating Effect of Prefrontal Asymmetry on the Relationship between the COMT Val158Met SNP and Trait Consummatory Positive Affect. Cognition & Emotion. 2015;29(5):867-881. https://doi.org/10.1080/02699931.2014.951030
  41. Eisenstein SA, Bogdan R, Chen L, Moerlein SM, Black KJ, Perlmutter JS, Hershey T, Barch DM. Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia. Journal of Psychiatric Research. 2017;86:9-17. https://doi.org/10.1016/j.jpsychires.2016.11.007
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.